Akero Therapeutics, Inc., A Clinical-Stage Company Developing Transformational Treatments For Patients With Serious Metabolic Disease Marked By High Unmet Medical Need, Today Announced That Efruxifermin (Efx) Has Received A Breakthrough Therapy Designation From The Us Food And Drug Administration (Fda) For The Treatment Of Nonalcoholic Steatohepatitis (Nash). There Are Currently No Approved Therapies For The Treatment Of Nash, Which Is A Serious Form Of Liver Disease Estimated To Affect 17 Million Americans.
